CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced it has received approval from Health Canada to extend the storage of platelets treated with the INTERCEPT Blood System ...

Platelet transfusion in neonates and children varies widely, with donor and processing factors linked to lower platelet increments and higher transfusion burden but not to mortality or length of stay.